



APEX HEALTHCARE BERHAD
(473108-T)
Incorporated in Malaysia

QUARTERLY REPORT ON CONSOLIDATED RESULTS FOR THE FINANCIAL QUARTER ENDED 31 DECEMBER 2000

THE FIGURES HAVE NOT BEEN AUDITED.

I. CONSOLIDATED INCOME STATEMENT

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	Current year quarter	Preceding year corresponding quarter	Current year to date	Preceding year corresponding period
	31/12/2000	31/12/1999	31/12/2000	31/12/1999
	RM'000	RM'000	RM'000	RM'000
1. (a) Turnover	28,000	NA	122,097	108,802
(b) Investment income	-	NA	-	-
(c) Other income including interest income	178	NA	535	30
2. (a) Operating profit/(loss) before interest on borrowings, depreciation and amortisation, exceptional items, income tax, minority interests and extraordinary items	3,334	NA	13,238	11,196
(b) Less: Interest on borrowings	(13)	NA	(320)	(423)
(c) Less: Depreciation and amortisation	(737)	NA	(2,596)	(2,007)
(d) Exceptional items	-	NA	-	-
(e) Operating profit/(loss) after interest on borrowings, depreciation and amortisation and exceptional items but before income tax, minority interests and extraordinary items	2,584	NA	10,322	8,766
(f) Share in the results of associated company	-	NA	-	-
(g) Profit/(Loss) before taxation, minority interests and extraordinary items	2,584	NA	10,322	8,766
(h) Taxation	(575)	NA	(2,218)	(180)
(i) (i) Profit/(Loss) after taxation before deducting minority interests	2,009	NA	8,104	8,586
(ii) Less: Minority interests	-	NA	-	-
(j) Profit/(Loss) after taxation attributable to members of the Company	2,009	NA	8,104	8,586
(k) (i) Extraordinary items	-	NA	-	-
(ii) Less: Minority interests	-	NA	-	-
(iii) Extraordinary items attributable to members of the Company	-	NA	-	-
(l) Profit/(Loss) after taxation and extraordinary items attributable to members of the Company	2,009	NA	8,104	8,586



APEX HEALTHCARE BERHAD
(473108-T)
Incorporated in Malaysia

I. CONSOLIDATED INCOME STATEMENT (Contd.)

		INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
		Current year quarter	Preceding year corresponding quarter	Current year to date	Preceding year corresponding period
		31/12/2000	31/12/1999	31/12/2000	31/12/1999
		RM'000	RM'000	RM'000	RM'000
3.	(a) Earnings per share based on 2(j) above:				
	(i) Basic (based on 39,153,068 ordinary shares)	<u>4.62 sen</u>	<u>NA</u>	<u>20.70 sen</u>	<u>25.33 sen</u>
	(ii) Fully diluted	<u>-</u>	<u>NA</u>	<u>-</u>	<u>-</u>
4.	(a) Dividend per share	<u>6.00 sen</u>	<u>NA</u>	<u>6.00 sen</u>	<u>NA</u>
	(b) Dividend description	The Directors recommend the payment of a first and final tax exempt dividend of 6 sen per share for the year ended 31 December 2000.			
				As at end of current quarter	As at preceding financial year end
				31/12/2000	31/12/1999
5.	Net tangible assets per share			<u>147 sen</u>	<u>115 sen</u>

Note

There are no comparative figures for the preceding year corresponding quarter as this is the first quarterly report prepared for the fourth quarter. The preceding year corresponding period figures are prepared on a proforma basis as if the Company had been in existence on 1 January 1999 and the merger had been effected on that date.



APEX HEALTHCARE BERHAD
(473108-T)
Incorporated in Malaysia

II CONSOLIDATED BALANCE SHEET

	Unaudited As at the end of current quarter 31/12/2000	Audited As at the preceding financial year ended 31/12/1999
	RM'000	RM'000
1. Fixed assets	27,878	17,554
2. Investment in associated companies	-	-
3. Other investments	-	-
4. Intangible assets		
Deferred expenditure	-	484
Others	-	13
	27,878	18,051
5. Current Assets		
Stocks	22,275	19,417
Trade debtors	22,857	22,900
Other debtors, deposits and prepayments	2,040	3,209
Term Deposits	11,703	3,500
Cash and bank balances	3,423	2,230
	62,298	51,256
6. Current Liabilities		
Trade creditors	11,577	13,005
Other creditors and accruals	6,155	8,728
Short term borrowings	4,784	5,788
Taxation	916	2
Proposed Dividend	2,604	1,410
	26,036	28,933
7. Net current assets	36,262	22,323
	64,140	40,374
8. Share capital	43,400	33,890
Reserves		
Share premium	3,439	-
Retained profits	11,193	5,693
Revaluation surplus reserve	5,628	-
Currency translation difference	13	-
	20,273	5,693
Shareholders' funds	63,673	39,583
9. Minority interests	-	-
10. Long term borrowings	-	112
11. Other long term and deferred liabilities		
Deferred taxation	-	169
Retirement benefits	467	510
	64,140	40,374
12. Net Tangible Assets per share	147 Sen	115 Sen



APEX HEALTHCARE BERHAD
(473108-T)
Incorporated in Malaysia

III. NOTES TO THE FINANCIAL STATEMENTS

1. The unaudited quarterly consolidated financial statements have been prepared by applying the same accounting policies, methods of computation and basis of consolidation consistent with those used for the year ended 31 December 1999 except for the revaluation of land and buildings of subsidiaries in April 2000. The surplus arising from the revaluation was incorporated in the financial statements in the quarter ended 30 June 2000.
2. There were no exceptional items in the results for the current financial quarter ended 31 December 2000.
3. There were no extraordinary items in the results for the current financial quarter ended 31 December 2000.
4. The tax figures include adjustments for deferred tax but exclude under or overprovision of tax in respect of prior years.
5. There were no pre-acquisition profits included in the results for the current financial quarter ended 31 December 2000
6. There were no sales of investments and/or properties during the current financial quarter ended 31 December 2000.
- 7a) There were no acquisitions or disposals of quoted securities for the current financial quarter ended 31 December 2000.
- 7b) There were no investments in quoted securities as at 31 December 2000.
8. For the current financial quarter ended 31 December 2000, the Group did not undertake any business combinations, acquisitions or disposals of subsidiaries and long term investments, restructuring or discontinuation of operations.
9. On 7th February 2001, the Group announced its proposal to implement an Employees' Share Option Scheme ("ESOS") for employees and Executive Directors of Apex Healthcare Berhad ("AHB") and its subsidiaries. The proposed ESOS is conditional upon and subject to approvals being obtained from the following:
 - (i) the Securities Commission for the Proposed ESOS as well as the submission of the Bye-Laws of the Proposed ESOS.
 - (ii) the KLSE for the Bye-Laws of the Proposed ESOS and the approval-in-principle for the listing of and quotation for the new AHB shares to be issued pursuant to the exercise of the options granted under the Proposed ESOS.
 - (iii) the shareholders of AHB at an Extraordinary General Meeting to be convened; and
 - (iv) any other relevant regulatory authorities.
10. The Group's operations were not subject to any seasonal or cyclical factors.
11. The Group and the Company did not undertake any issuance and/or repayment of debt and equity securities, share buy-backs, share cancellations, shares held as treasury shares and resale of treasury shares during the current financial quarter ended 31 December 2000.
12. The details of the Group's short term borrowings denominated in Ringgit Malaysia as at 31 December 2000 are as follows:

	Short term borrowings		
	Secured	Unsecured	Total
	RM'000	RM'000	RM'000
Domestic			
- Banks	1,670	3,114	4,784
- Others	-	-	-
TOTAL	1,670	3,114	4,784

The Group does not have any long term borrowings and debt securities as at 31 December 2000.

13. The Group does not have any contingent liabilities as at the date of this announcement.
14. There were no financial instruments with off-balance sheet risks as at the date of this announcement.
15. The Company and its subsidiaries have no outstanding material litigations as at the date of this announcement.
16. Segmental reporting is not applicable as the Group's pharmaceutical business is principally based in Malaysia.



APEX HEALTHCARE BERHAD
(473108-T)
Incorporated in Malaysia

17. The Group achieved a Profit before Taxation of RM 2.58 million for the quarter under review as compared to RM 2.54 million for the third quarter.
18. **Review of Performance for the Current Quarter**
- The Group recorded a turnover of RM28 million and profit before tax of RM 2.58 million for the current quarter ended 31 December 2000. Core activities of pharmaceutical manufacturing, distribution and retailing performed satisfactorily and are within the expectations of the Board of Directors.
- In the current quarter, a new retail pharmacy outlet was opened at First World Hotel in Genting Highlands. The Group's manufacturing subsidiary, Xepa-Soul Pattinson (Malaysia) Sdn Bhd launched ZYNACE[®], which is used for the treatment of hypertension, and ZENPRO[®], which is for the treatment of peptic ulcers.
- In the opinion of the Directors, there are no items, transactions or events of a material and unusual nature which have arisen from 31 December 2000 to the date of this announcement, which would substantially affect the financial results of the Group and of the Company for the year ended 31 December 2000.
19. **Prospects for the Current Year**
- The slow down in the U.S. and regional economies is expected to have an impact on the Malaysian economy. However, the Group will continue to expand market share by opening new retail pharmacy outlets and introduce new pharmaceutical products. Together with efforts to streamline operations, the Group expects to achieve a satisfactory performance in the current year, barring unforeseen circumstances.
20. **Profit Forecast**
- The consolidated profit after tax of the Group for the year of RM 8.10 million exceeds the profit forecast of RM 7.83 million submitted to the authorities in conjunction with the Company's initial public offering by 3.4%.
21. **Dividend**
- For the financial year ended 31 December 2000, the Board of Directors is recommending a first and final tax exempt dividend of 6 sen per share for shareholders' approval at the forthcoming Annual General Meeting of the Company. The date of the Annual General Meeting and the date of book closure for the final dividend payment will be announced in due course.